Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Pfizer ( PFE) said its Phase 2 study of tilrekimig (PF-07275315), a trispecific antibody for atopic dermatitis, showed positive results.

Meta Platforms, Netflix and Pfizer lead fresh research as AI bets, bold 2030 goals and patent cliffs shape their outlooks.

Includes a one-time $1.35 billion Acquired In-Process R&D charge related to the in-licensing agreement with 3SBio, Inc. recorded in the third quarter of 2025 with an unfavorable impact of ...

Pfizer (NYSE: PFE) recently reported earnings, and its payout ratio is once again over 100%. Given that the stock is paying a fairly high yield of 6.4%, which is far above the S&P 500 average of 1.2%, ...

Pfizer reports second-quarter earnings on Tuesday, before the market opens, as investors struggle to see anything in the stock to get excited about. Shares of the drug maker are down more than 10% ...

$2.2 billion invested in internal research and development projects, and Approximately $90 million invested in business development transactions. Returning capital directly to shareholders through ...

Merck & Co.'s Keytruda in combination with an antibody-drug conjugate from Pfizer and Astellas Pharma led to a 47% reduction in the risk of tumor recurrence, progression or death in patients with ...

Pfizer's stock has been trading at low levels for a while. Diminished growth and concerns about the future have investors thinking twice about the stock. The company did show signs of progress in its ...

WASHINGTON, D.C. -- A major drug company is defending itself against accusations it kept promising and possibly life-saving data secret. The Washington Post reports that Pfizer decided against sharing ...

A Pfizer Inc. contract provision requiring employees to keep the subject and materials of arbitration proceedings ...